A gratifying clinical response obtained in the setting of bilateral orbital metastases from renal
neuroendocrine tumor is reported. Methods: A 53-y-old man diagnosed with renal …

Neuroendocrine tumors have a propensity to metastasize to the orbit, although the reason is
unknown. A review of 251 neuroendocrine tumors treated with 177 Lu-DOTATATE or 131 I …

Metastatic tumor is one of several etiologies of space-occupying masses in the orbit that
accounts for 1-13% of all orbital masses. In the adult patient population, breast cancer is the …

Neuroendocrine tumors have a propensity to metastasize, but rarely to the orbits. A 69-year-
old woman with history of neuroendocrine tumor of pancreatic primary underwent routine …

The aim of this study was to evaluate the response and hematological toxicity in peptide
receptor radionuclide therapy (PRRT) with lutetium (177 Lu)-DOTA-octreotate (DOTATATE) …

Discussion Orbital metastases are rare and have widely differing diagnoses, including
lymphoma, carcinoma (most commonly breast or gastrointestinal), melanoma, or other …

Thyroid gland and orbit are rare sites of metastases in neuroendocrine tumors. We present
an extremely rare case of rectal neuroendocrine tumor with metastases to thyroid gland and …

Aims and Objectives: Assessment of renal toxicity profile of 177 Lu-DOTATATE based
Peptide Receptor Radionuclide therapy (PRRT) in patients of Metastatic Neuroendocrine …

Our objective was to assess the renal toxicity profile of 177Lu-DOTATATE peptide receptor
radionuclide therapy (PRRT) in patients with a metastatic neuroendocrine tumor (NET) and …

Neuroendocrine tumors (NETs) rarely metastasize to the brain. However, when they occur,
NET brain metastases are associated with a poor prognosis. Due to their low incidence, NET …